Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IDEAYA Biosciences, Inc. (IDYA : NSDQ)
 
 • Company Description   
IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States.

Number of Employees: 81

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.43 Daily Weekly Monthly
20 Day Moving Average: 323,273 shares
Shares Outstanding: 38.64 (millions)
Market Capitalization: $403.01 (millions)
Beta: 1.78
52 Week High: $28.00
52 Week Low: $8.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.29% 9.26%
12 Week -23.42% -16.91%
Year To Date -55.88% -47.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7000 SHORELINE COURT SUITE 350
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-443-6209
fax: -
investor@ideayabio.com http://www.ideayabio.com
 
 • General Corporate Information   
Officers
Yujiro Hata - Chief Executive Officer and President
Timothy Shannon - Chairman of the Board of Directors
Paul Stone - Senior Vice President and Chief Financial Officer
Garret Hampton - Director
Susan L. Kelley - Director

Peer Information
IDEAYA Biosciences, Inc. (CORR.)
IDEAYA Biosciences, Inc. (RSPI)
IDEAYA Biosciences, Inc. (CGXP)
IDEAYA Biosciences, Inc. (BGEN)
IDEAYA Biosciences, Inc. (GTBP)
IDEAYA Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45166A102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 38.64
Most Recent Split Date: (:1)
Beta: 1.78
Market Capitalization: $403.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.40
Price/Cash Flow: -
Price / Sales: 12.57
EPS Growth
vs. Year Ago Period: -28.57%
vs. Previous Quarter: 23.40%
Sales Growth
vs. Year Ago Period: 56.74%
vs. Previous Quarter: 283.36%
ROE
03/31/22 - -19.08
12/31/21 - -18.22
09/30/21 - -14.83
ROA
03/31/22 - -14.92
12/31/21 - -13.87
09/30/21 - -10.85
Current Ratio
03/31/22 - 4.50
12/31/21 - 5.56
09/30/21 - 6.96
Quick Ratio
03/31/22 - 4.50
12/31/21 - 5.56
09/30/21 - 6.96
Operating Margin
03/31/22 - -170.82
12/31/21 - -178.09
09/30/21 - -103.19
Net Margin
03/31/22 - -170.82
12/31/21 - -178.09
09/30/21 - -103.19
Pre-Tax Margin
03/31/22 - -170.82
12/31/21 - -178.10
09/30/21 - -103.19
Book Value
03/31/22 - 7.47
12/31/21 - 7.83
09/30/21 - 8.27
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©